Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $151,746.00 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,200 shares of Neurogene stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the transaction, the chief financial officer directly owned 84,040 shares of the company’s stock, valued at approximately $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Monday, July 6th, Christine Mikail Cvijic sold 600 shares of Neurogene stock. The stock was sold at an average price of $36.02, for a total value of $21,612.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $42.84 on Friday. The firm has a market capitalization of $676.96 million, a PE ratio of -9.42 and a beta of 1.68. Neurogene Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $43.66. The stock’s 50-day simple moving average is $30.23 and its 200-day simple moving average is $23.86.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.09). On average, sell-side analysts forecast that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NGNE has been the topic of several research analyst reports. Rodman & Renshaw assumed coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Canaccord Genuity Group lowered their price target on shares of Neurogene to $180.00 and set a “buy” rating for the company in a report on Monday, April 6th. UBS Group set a $70.00 price objective on Neurogene in a research report on Wednesday, June 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a report on Tuesday, June 9th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Neurogene presently has a consensus rating of “Buy” and an average price target of $84.83.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. acquired a new position in Neurogene in the 3rd quarter worth $12,114,000. ArrowMark Colorado Holdings LLC lifted its holdings in Neurogene by 1.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after acquiring an additional 10,442 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after purchasing an additional 138,999 shares during the last quarter. State Street Corp lifted its stake in Neurogene by 47.8% in the fourth quarter. State Street Corp now owns 307,797 shares of the company’s stock valued at $6,341,000 after buying an additional 99,487 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Neurogene by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock valued at $5,145,000 after purchasing an additional 3,262 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.